ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses847 K2.13 M2.31 M1.46 M1.27 M7.17 MResearch & development2.24 M1.46 M2.21 M1.03 M1.15 M5.85 MOperating income3.09 M3.6 M4.5 M2.49 M2.43 M13.01 MNon-Operating Income, Total-15.42 M-1.62 M2.56 M10.25 M61.47 M72.66 MInterest expense, net of interest capitalized000000Non-Operating Income, excl. Interest Expenses-15.42 M-1.62 M-1.06 M10.25 M61.47 M69.05 MUnusual income/expense——3.62 M———Pretax income-6.24 M9.78 M7.06 M-982 K59.45 M75.31 MEquity in earnings——————Taxes1.13 M416 K584 K-126 K11.06 M11.94 MNon-controlling/minority interest23 K10 K028 K6 00044 KAfter tax other income/expense——————Net income before discontinued operations-1.88 M10.23 M7.64 M-2 M48.4 M64.27 MDiscontinued operations——————Net income-1.88 M10.23 M7.64 M-2 M48.4 M64.27 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-1.88 M10.23 M7.64 M-2 M48.4 M64.27 MBasic earnings per share (Basic EPS)-0.48-0.26-0.190.331.161.04Diluted earnings per share (Diluted EPS)-0.48-0.26-0.190.321.131Average basic shares outstanding40.88 M40.83 M41.23 M41.49 M41.57 M165.12 MDiluted shares outstanding40.88 M40.83 M41.23 M42.88 M42.97 M167.91 MEBITDA——-2.44 M-1.43 M-1.24 M—EBIT——-2.47 M-1.46 M-1.27 M—Cost of revenue——1.99 M00—Other cost of goods sold——————Depreciation & amortization (cash flow)52 K31 K30 K30 K31 K122 K
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.